Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Trial details
- Registry ID
- NCT06790966
- Drugs studied
- Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
TrialRedline tracks 2 clinical trials sponsored by PDS Biotechnology Corp.: 1 Phase 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNCT06790966 | Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy | Terminated | 2026-08-25Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCNCT04260126 | Pembrolizumab (KEYTRUDA®) and PDS0101 | Completed | 2025-05-14Actual |
Names as written in the registry records.
NCT06790966 · PDS Biotechnology Corp.
Before: Estimated. After: Actual.
Before: 252 participants (planned). After: 12 participants (actual).
Before: Estimated. After: Actual.
Before: Feb 2029. After: 25 Aug 2026.
Before: Active not recruiting. After: Terminated.
NCT06790966 · PDS Biotechnology Corp.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Overall Survival (OS). After: Measure: Overall Survival (OS) Measure: Progression-Free Survival (PFS).
Before: 351 participants (planned). After: 252 participants (planned).